Latest News and Press Releases

Interim analysis performed with initial 150 U.S. patient samples enrolled in its prospective multicenter trial for the Unyvero UTI panel - Clinical Trial to be continued without any...

Total revenue for 2021 was approximately $4.3 millionStrong total cash position of approximately $36.1 million as of December 31, 2021, up significantly from $13.4 million at year-end 2020Conference...

ROCKVILLE, Md., March 15, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its fourth quarter...

Publication demonstrates FDA cleared Acuitas AMR Gene Panel detects and differentiates a broad range of 28 AMR markers that can be associated with up to 9 antimicrobial classes Provides results at...

Unyvero A30 RQ analyzer successfully completed verification and validation (V&V) testing as well as lifetime testingUnyvero A30 instruments met all V&V criteria for series-production systems ...

ROCKVILLE, Md., Jan. 18, 2022 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat...

Preliminary unaudited revenue for 2021 was approximately $4.3 millionMaintained strong balance sheet with $36.1 million cash as of December 31, 2021 and total capital raised in 2021 of $51.2...

Following successful completion of Phase 1, Ares Genetics has now entered into Phase 2 of its collaboration with a leading U.S. CRO and reference lab, gaining access to 1,000 proprietary clinical...

ROCKVILLE, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to...

Ares Genetic is granting a permanent, unrestricted and non-exclusive access to a small subset of the proprietary ARESdb data asset to an unnamed global corporation and leader in microbiology and...